Effective treatment of severe COVID-19 patients with tocilizumab
530
Published on
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, MERS, SARS,
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, MERS, SARS,
[키워드] absorbed
activated
addition
Adverse reaction
analyzed
average
binding
C-reactive protein
change
China
clinical manifestations
Clinical outcome
Computerized tomography
coronavirus disease
COVID-19
Critical
critical COVID-19 patients
CT scan
cytokine
Cytokine storm
diagnosed
discharged
effective
Efficacy
elevated
high affinity
humanized
IL-6
IL-6 receptor
immune
immune characteristics
inflammatory monocyte
Inflammatory response
Inflammatory responses
inflammatory storm
interleukin-6
Laboratory
lung
lymphocyte
manifested
monoclonal antibody
mononuclear macrophage
organs
other tissue
oxygen
Oxygen therapy
pathogenic
Pathways
Patient
Peripheral blood
producing
receptor
reduce mortality
returned
SARS-CoV-2
Science
second
secreting
severe coronavirus disease
severe COVID-19 patient
Severe patient
Significance
significantly
Symptom
T cell
T lymphocyte
target
target cells
technology
the cytokine storm
therapeutic strategy
therapy
Tocilizumab
Treatment
university
were given
with COVID-19
[DOI] 10.1073/pnas.2005615117 PMC 바로가기 [Article Type] 530
[DOI] 10.1073/pnas.2005615117 PMC 바로가기 [Article Type] 530